However, due to its ability to lower glucose, insulin, and free fatty acids, as well as to disrupt the insulin/IGF-1-PI3K/AKT/mTOR and fatty acid/lipid biosynthetic pathways, metformin may serve as a metabolically targeted therapy for obesity-driven cancers, thereby eliminating the association between obesity and cancer [109,212,213,214]. This evidence concerns the gene IGF1 and cancer.